Publications

Annals of oncology : official journal of the European Society for Medical Oncology

Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer.

01-03-2026

European urology oncology

Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer.

01-08-2025

Cell reports. Medicine

Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer.

15-07-2025

Communications biology

TRIM33 loss reduces androgen receptor transcriptional output and H2BK120 ubiquitination.

11-07-2025

Clinical genitourinary cancer

Learning From Evidence: Changes in Real-World Use of Second Androgen Receptor Targeted Treatments in Metastatic Castration-Resistant Prostate Cancer (mCRPC).

01-06-2025

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.

10-05-2025

British journal of cancer

Feasibility and efficacy of therapeutic drug monitoring of abiraterone in metastatic castration resistant prostate cancer patients.

01-04-2025

The Journal of clinical investigation

Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice.

19-11-2024

European urology oncology

Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study.

01-10-2024

Cancers

It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective.

10-01-2024

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide.

31-12-2023

European urology

Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs.

01-11-2023

Cancer research communications

Exploring the Onset and Progression of Prostate Cancer through a Multicellular Agent-based Model.

01-08-2023

Cancers

Radiogenomics Analysis Linking Multiparametric MRI and Transcriptomics in Prostate Cancer.

06-06-2023

Cancers

Treating Primary Node-Positive Prostate Cancer: A Scoping Review of Available Treatment Options.

29-05-2023

Prostate cancer and prostatic diseases

Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry.

01-03-2023

Urologic oncology

Predictive value of low testosterone concentrations during and prior to enzalutamide treatment in metastatic castration-resistant prostate cancer.

01-02-2023

Nature communications

Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.

30-11-2022

Endocrinology

Homing in on a Moving Target: Androgen Receptor Cistromic Plasticity in Prostate Cancer.

11-10-2022

Clinical chemistry and laboratory medicine

Testosterone analysis in castrated prostate cancer patients: suitability of the castration cut-off and analytical accuracy of the present-day clinical immunoassays.

27-09-2022

Advances in experimental medicine and biology

Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications.

16-09-2022

Cancer discovery

Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.

02-09-2022

Drugs - real world outcomes

Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer.

01-06-2022

Cancer chemotherapy and pharmacology

Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients.

01-06-2022

Clinical epigenetics

Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer.

04-05-2022

Clinical genitourinary cancer

A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer.

01-04-2022

Clinical genitourinary cancer

Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands.

01-02-2022

Cell reports

Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer.

14-12-2021

Journal of palliative medicine

High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients: Results from the Dutch CAPRI-Registry.

01-12-2021

Nature communications

Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer.

04-11-2021

Clinica chimica acta; international journal of clinical chemistry

Retrospective analysis of serum testosterone levels by LC-MS/MS in chemically castrated prostate cancer patients: Biological variation and analytical performance specifications.

01-10-2021

Molecular cancer research : MCR

The Prognostic Potential of Human Prostate Cancer-Associated Macrophage Subtypes as Revealed by Single-Cell Transcriptomics.

01-10-2021

Nature cell biology

An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.

01-09-2021

Prostate cancer and prostatic diseases

The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population.

01-09-2021

Cancers

Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation.

27-08-2021

Cancer reports (Hoboken, N.J.)

ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study.

01-08-2021

Molecular oncology

Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases.

01-07-2021

Cancer chemotherapy and pharmacology

Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours.

01-06-2021

Genome biology

Functional mapping of androgen receptor enhancer activity.

11-05-2021

Future oncology (London, England)

The intravenous to oral switch of taxanes: strategies and current clinical developments.

01-04-2021

Nature communications

The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair.

15-01-2021

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients.

01-01-2021

BMC cancer

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.

14-09-2020

Nature communications

Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion.

09-09-2020

Key

International journal of cancer

A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.

15-08-2020

Nucleosides, nucleotides & nucleic acids

Effect of dexamethasone on the antileukemic effect of cytarabine: role of deoxycytidine kinase.

31-07-2020

bioRxiv

Human Prostate Cancer-Associated Macrophage Subtypes and Prognostic Potential Revealed by Single-cell Transcriptomics

20-06-2020

Key

Prostate cancer and prostatic diseases

Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer.

01-06-2020

European journal of cancer (Oxford, England : 1990)

Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme.

01-05-2020

Clinical genitourinary cancer

Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer.

01-02-2020